BACKGROUND: The use of high-dose chemotherapy and autologous stem-cell transplantation in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials but its benefit in patients with primary refractory disease is less clear. Aiming to shed light on this issue, we analyzed and compared the outcomes of patients with relapsed or refractory Hodgkin's lymphoma treated with second-line chemotherapy and planned autologous stem-cell transplantation. DESIGN AND METHODS: We retrospectively analyzed data on 157 consecutive patients with Hodgkin's lymphoma referred to our institution for consideration of autologous stem-cell transplantation between 1999 and 2006. Of those, 73 met the definition of having primary refractory disease, ie. progressive disease during first line chemotherapy or within 3 months of completion of the treatment. Those patients achieving complete remission, partial remission and stable disease with symptomatic improvement after two or three cycles of salvage chemotherapy proceeded to stem cell mobilization and autologous transplantation. RESULTS: From first relapse/progression, the 3-year overall survival was 76% (95% CI: 66%-89%) for the refractory cohort and 91% (95% CI: 84%-98%) for the relapsed cohort (P=0.034); the overall response rate to second-line chemotherapy was 51% and 83% (P<0.0001), respectively. Three-year progression-free survival post-transplant was 49% in refractory patients and 67% in relapsed patients (P=0.21); overall survival was 75% and 91% (P=0.097), respectively. CONCLUSIONS: Using the group with relapsed disease as a reference, we can conclude that the subset of patients with chemosensitive primary refractory Hodgkin's lymphoma do benefit from autologous stem-cell transplantation.
BACKGROUND: The use of high-dose chemotherapy and autologous stem-cell transplantation in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials but its benefit in patients with primary refractory disease is less clear. Aiming to shed light on this issue, we analyzed and compared the outcomes of patients with relapsed or refractory Hodgkin's lymphoma treated with second-line chemotherapy and planned autologous stem-cell transplantation. DESIGN AND METHODS: We retrospectively analyzed data on 157 consecutive patients with Hodgkin's lymphoma referred to our institution for consideration of autologous stem-cell transplantation between 1999 and 2006. Of those, 73 met the definition of having primary refractory disease, ie. progressive disease during first line chemotherapy or within 3 months of completion of the treatment. Those patients achieving complete remission, partial remission and stable disease with symptomatic improvement after two or three cycles of salvage chemotherapy proceeded to stem cell mobilization and autologous transplantation. RESULTS: From first relapse/progression, the 3-year overall survival was 76% (95% CI: 66%-89%) for the refractory cohort and 91% (95% CI: 84%-98%) for the relapsed cohort (P=0.034); the overall response rate to second-line chemotherapy was 51% and 83% (P<0.0001), respectively. Three-year progression-free survival post-transplant was 49% in refractory patients and 67% in relapsed patients (P=0.21); overall survival was 75% and 91% (P=0.097), respectively. CONCLUSIONS: Using the group with relapsed disease as a reference, we can conclude that the subset of patients with chemosensitive primary refractory Hodgkin's lymphoma do benefit from autologous stem-cell transplantation.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: A Martín; M C Fernández-Jiménez; M D Caballero; M A Canales; J A Pérez-Simón; J García de Bustos; L Vázquez; F Hernández-Navarro; J F San Miguel Journal: Br J Haematol Date: 2001-04 Impact factor: 6.998
Authors: S J Horning; J Williams; N L Bartlett; J M Bennett; R T Hoppe; D Neuberg; P Cassileth Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544
Authors: Andreas Josting; Jeremy Franklin; Michael May; Peter Koch; Maria K Beykirch; Juergen Heinz; Christian Rudolph; Volker Diehl; Andreas Engert Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Philippe Armand; Margaret A Shipp; Vincent Ribrag; Jean-Marie Michot; Pier Luigi Zinzani; John Kuruvilla; Ellen S Snyder; Alejandro D Ricart; Arun Balakumaran; Shelonitda Rose; Craig H Moskowitz Journal: J Clin Oncol Date: 2016-11-01 Impact factor: 44.544
Authors: Kevin C Conlon; Claude Sportes; Martin W Brechbiel; Daniel H Fowler; Ronald Gress; Milos D Miljkovic; Clara C Chen; Millie A Whatley; Bonita R Bryant; Erin M Corcoran; Karen A Kurdziel; Stefania Pittaluga; Chang H Paik; Jae Ho Lee; Thomas A Fleisher; Jorge A Carrasquillo; Thomas A Waldmann Journal: Cancer Biother Radiopharm Date: 2020-04-09 Impact factor: 3.099
Authors: Anna Czyz; Anna Lojko-Dankowska; Dominik Dytfeld; Adam Nowicki; Lidia Gil; Magdalena Matuszak; Maria Kozlowska-Skrzypczak; Maciej Kazmierczak; Ewa Bembnista; Mieczysław Komarnicki Journal: Med Oncol Date: 2013-05-24 Impact factor: 3.064